NCT07516561

Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

Phase III Randomized, Multicenter, Double-blind, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 336 (estimated)
• Sponsor: Apsen Farmaceutica S.A. · Industry
• Sex: Male
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.

Conditions

• Alopecia, Androgenetic

Interventions

Type	Name	Description
DRUG	APSMNF 1	Administer twice a day during 24 weeks.
DRUG	APSMNF 2	Administer twice a day during 24 weeks.
DRUG	Eniagor®	Administer twice a day during 24 weeks.

Timeline

• Start date: 2026-07-07
• Primary completion: 2029-08-02
• Completion: 2029-08-02
• First posted: 2026-04-08
• Last updated: 2026-04-13

Locations

1 site across 1 country: Brazil